Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) Financials

$26.04 +0.02 (+0.06%)

Closing price 05/23/2025 03:43 PM Eastern

Extended Trading

$26.13 +0.10 (+0.38%)

As of 05/23/2025 04:07 PM Eastern

Annual Income Statements for Harrow Health, Inc. 11.875% Senior Notes due 2027

This table shows Harrow Health, Inc. 11.875% Senior Notes due 2027's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	-17	-24	-14	-18	-3.36	0.17	15	-12	-19	-16	-10
Consolidated Net Income / (Loss)	-17	-24	-14	-18	-3.42	-0.13	15	-12	-19	-16	-10
Net Income / (Loss) Continuing Operations	-17	-24	-14	-18	-3.42	-0.13	15	-12	-19	-16	-10
Total Pre-Tax Income	-17	-24	-14	-18	-3.42	-0.12	15	-13	-19	-16	-10
Total Operating Income	8.82	0.43	1.92	1.61	0.39	-4.80	-5.22	-12	-16	-15	-10
Total Gross Profit	150	91	63	54	34	34	25	13	10	4.51	0.57
Total Revenue	200	130	89	72	49	51	41	27	20	9.72	1.66
Operating Revenue	200	130	89	72	49	51	41	27	20	9.72	1.66
Total Cost of Revenue	49	40	25	18	14	17	17	14	9.83	5.21	1.09
Operating Cost of Revenue	49	40	25	18	14	17	17	14	9.83	5.21	1.09
Total Operating Expenses	142	90	61	53	34	39	30	25	26	19	11
Selling, General & Admin Expense	129	83	58	41	31	33	29	25	18	13	8.09
Research & Development Expense	12	6.65	3.05	11	2.41	2.08	0.83	0.41	0.74	0.33	0.24
Impairment Charge	0.25	0.38	0.00	0.25	0.36	4.04	0.00	-	0.30	0.00	-
Total Other Income / (Expense), net	-26	-24	-16	-19	-3.80	4.68	20	-0.76	-3.32	-1.08	0.03
Interest Expense	23	27	7.24	6.19	2.24	2.50	2.73	3.03	4.74	1.11	-0.03
Interest & Investment Income	-3.17	3.09	-2.91	-10	3.26	6.55	23	3.51	0.00	-	-
Other Income / (Expense), net	-0.19	-0.44	-5.77	-3.17	-4.82	0.63	-0.29	-1.24	1.42	0.03	0.00
Income Tax Expense	0.16	0.70	0.08	0.13	0.00	0.01	0.00	-0.94	-0.11	0.00	-
Basic Earnings per Share	($0.49)	($0.75)	($0.51)	($0.69)	($0.13)	$0.01	$0.67	($0.60)	($1.50)	($1.66)	($1.11)
Weighted Average Basic Shares Outstanding	35.65M	32.62M	27.46M	26.76M	25.90M	25.32M	21.92M	20.03M	12.74M	9.58M	9.13M
Diluted Earnings per Share	($0.49)	($0.75)	($0.51)	-	($0.13)	$0.01	$0.61	($0.60)	($1.50)	($1.66)	($1.11)
Weighted Average Diluted Shares Outstanding	35.65M	32.62M	27.46M	26.76M	25.90M	26.47M	23.81M	20.03M	12.74M	9.58M	9.13M
Weighted Average Basic & Diluted Shares Outstanding	35.65M	35.36M	29.97M	26.76M	25.90M	25.53M	24.69M	20.03M	12.74M	9.58M	9.13M

This table shows Harrow Health, Inc. 11.875% Senior Notes due 2027's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-18	6.78	-4.22	-6.47	-14	-9.15	-4.39	-4.23	-6.64	1.06	-6.46
Consolidated Net Income / (Loss)	-18	6.78	-4.22	-6.47	-14	-9.15	-4.39	-4.23	-6.64	1.06	-6.46
Net Income / (Loss) Continuing Operations	-18	6.78	-4.22	-6.47	-14	-9.15	-4.39	-4.23	-6.64	1.06	-6.46
Total Pre-Tax Income	-18	6.26	-4.20	-5.82	-14	-9.68	-2.85	-4.24	-6.93	1.06	-6.43
Total Operating Income	-11	13	1.32	1.53	-6.93	-4.88	1.74	2.35	1.21	-1.78	-0.09
Total Gross Profit	32	53	37	36	24	25	24	23	18	14	16
Total Revenue	48	67	49	49	35	36	34	33	26	20	23
Operating Revenue	48	67	49	49	35	36	34	33	26	20	23
Total Cost of Revenue	16	14	12	13	11	11	10	10	8.27	6.17	6.72
Operating Cost of Revenue	16	14	12	13	11	11	10	10	8.27	6.17	6.72
Total Operating Expenses	44	40	36	35	31	30	22	21	17	16	16
Selling, General & Admin Expense	41	35	34	32	29	26	21	20	16	15	15
Research & Development Expense	3.03	4.76	2.27	3.05	2.15	3.34	1.42	1.16	0.73	0.70	0.78
Total Other Income / (Expense), net	-6.55	-6.64	-5.52	-7.35	-6.64	-4.81	-4.60	-6.60	-8.14	2.83	-6.34
Interest Expense	6.55	6.38	5.53	5.47	5.42	5.12	5.75	5.70	10	1.86	1.80
Interest & Investment Income	0.00	-	0.00	-1.92	-1.25	0.42	1.35	-0.71	2.04	1.43	-1.03
Other Income / (Expense), net	0.00	-0.26	0.00	0.05	0.03	-0.10	-0.20	-0.18	0.03	3.26	-3.50
Basic Earnings per Share	($0.50)	$0.19	($0.12)	($0.18)	($0.38)	($0.26)	($0.13)	($0.14)	($0.22)	$0.05	($0.24)
Weighted Average Basic Shares Outstanding	35.83M	35.65M	35.70M	35.62M	35.47M	32.62M	34.26M	30.46M	30.29M	27.46M	27.35M
Diluted Earnings per Share	($0.50)	$0.19	($0.12)	($0.18)	($0.38)	($0.26)	($0.13)	($0.14)	($0.22)	-	($0.24)
Weighted Average Diluted Shares Outstanding	35.83M	35.65M	35.70M	35.62M	35.47M	32.62M	34.26M	30.46M	30.29M	27.46M	27.35M
Weighted Average Basic & Diluted Shares Outstanding	36.70M	35.65M	35.61M	35.48M	35.38K	35.36M	35.12M	35.12M	30.12M	29.97M	27.41M

This table details how cash moves in and out of Harrow Health, Inc. 11.875% Senior Notes due 2027's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	-27	-22	54	38	-0.65	-1.89	2.62	-6.60	6.17	-5.53	-7.37
Net Cash From Operating Activities	-22	3.84	1.71	5.08	-1.10	0.95	0.69	-8.80	-11	-11	-7.06
Net Cash From Continuing Operating Activities	-22	3.84	1.71	5.08	-1.10	0.95	0.69	-11	-11	-11	-7.06
Net Income / (Loss) Continuing Operations	-17	-24	-14	-18	-3.42	-0.13	15	-12	-19	-16	-10
Consolidated Net Income / (Loss)	-17	-24	-14	-18	-3.42	-0.13	15	-12	-19	-16	-10
Depreciation Expense	1.85	1.53	1.48	1.72	1.88	1.94	1.61	1.40	1.06	0.26	0.04
Amortization Expense	17	15	2.97	1.36	1.32	1.24	0.85	1.34	1.32	0.64	0.05
Non-Cash Adjustments To Reconcile Net Income	21	19	17	20	5.39	-0.38	-20	-0.26	6.18	3.54	2.62
Changes in Operating Assets and Liabilities, net	-45	-7.14	-5.57	-0.25	-6.27	-1.72	3.44	0.70	-0.68	0.33	0.36
Net Cash From Investing Activities	-33	-153	-1.74	-19	-0.98	-1.83	-2.20	-0.96	-7.29	-5.13	-0.91
Net Cash From Continuing Investing Activities	-33	-153	-1.74	-19	-0.98	-1.83	-2.20	-0.96	-7.29	-2.09	-0.91
Purchase of Property, Plant & Equipment	-1.60	-1.46	-2.60	-1.79	-0.86	-1.47	-1.77	-0.77	-6.89	-1.52	-0.17
Acquisitions	-0.08	-0.02	-0.18	-0.08	-0.13	-0.37	-0.44	-0.25	-0.35	-3.61	-0.64
Sale and/or Maturity of Investments	5.51	0.00	-	9.83	0.00	-	-	-	-	-	-
Other Investing Activities, net	-37	-151	1.00	-27	0.00	-	0.00	-0.05	0.00	-	-
Net Cash From Financing Activities	29	127	54	51	1.43	-1.01	4.13	4.93	25	11	0.60
Net Cash From Continuing Financing Activities	29	127	54	51	1.43	-1.01	4.13	4.93	25	11	0.63
Repayment of Debt	0.00	-60	-0.02	-16	-1.51	-1.49	-0.74	-15	-0.46	-0.16	-0.01
Issuance of Debt	30	134	32	71	2.97	0.00	-	16	4.71	9.27	-
Issuance of Common Equity	0.00	65	23	0.00	-	-	0.64	4.06	21	0.40	0.00
Other Financing Activities, net	-1.25	-13	-0.23	-3.16	-0.03	0.49	4.23	0.18	-0.09	1.24	0.62
Cash Interest Paid	21	19	6.48	4.82	1.79	1.97	2.10	1.54	1.37	0.64	0.00
Cash Income Taxes Paid	0.37	0.00	0.08	0.01	0.00	0.02	0.00	0.01	0.01	0.00	0.00

This table details how cash moves in and out of Harrow Health, Inc. 11.875% Senior Notes due 2027's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	19	-25	1.63	2.43	-5.55	8.48	43	3.51	-77	51	-1.48
Net Cash From Operating Activities	20	-18	2.95	-2.75	-4.63	8.70	-1.21	4.57	-8.21	-3.71	-0.41
Net Cash From Continuing Operating Activities	20	-18	2.95	-2.75	-4.63	8.70	-1.21	4.57	-8.21	-3.71	-0.41
Net Income / (Loss) Continuing Operations	-18	6.78	-4.22	-6.47	-14	-9.15	-4.39	-4.23	-6.64	1.06	-6.46
Consolidated Net Income / (Loss)	-18	6.78	-4.22	-6.47	-14	-9.15	-4.39	-4.23	-6.64	1.06	-6.46
Depreciation Expense	0.47	0.47	0.50	0.45	0.43	0.44	0.41	0.40	0.29	0.39	0.25
Amortization Expense	5.72	5.56	3.88	3.72	3.72	4.16	3.71	3.89	3.15	0.75	0.77
Non-Cash Adjustments To Reconcile Net Income	4.67	5.19	4.46	6.18	5.33	4.55	3.19	6.14	5.08	-2.44	6.47
Changes in Operating Assets and Liabilities, net	27	-36	-1.67	-6.63	-0.55	8.70	-4.12	-1.62	-10	-3.46	-1.43
Net Cash From Investing Activities	-0.21	-38	-0.60	5.10	-0.11	-0.20	-20	-1.25	-131	-0.01	-1.07
Net Cash From Continuing Investing Activities	-0.21	-38	-0.60	5.10	-0.11	-0.20	-20	-1.25	-131	-0.01	-1.07
Purchase of Property, Plant & Equipment	-0.17	-0.56	-0.60	-0.34	-0.09	-0.19	-0.52	-0.25	-0.50	-0.88	-1.06
Acquisitions	-0.04	-0.01	0.01	-0.06	-0.02	-0.02	-	-	0.00	-0.16	-0.01
Net Cash From Financing Activities	0.02	30	-0.72	0.07	-0.81	-0.02	64	0.19	62	55	-
Net Cash From Continuing Financing Activities	0.02	30	-0.72	0.07	-0.81	-0.02	64	0.19	62	55	-
Other Financing Activities, net	0.02	0.11	-0.72	0.17	-0.81	-74	61	-4.77	4.45	0.65	-
Cash Interest Paid	6.39	5.04	5.24	4.98	5.34	6.61	4.20	4.71	3.37	1.63	1.62
Cash Income Taxes Paid	0.04	0.37	-	-	0.00	-	-0.00	0.00	0.00	-	0.04

This table presents Harrow Health, Inc. 11.875% Senior Notes due 2027's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Assets	389	312	157	98	57	59	49	24	27	14	10
Total Current Assets	190	139	118	61	41	36	33	8.81	15	5.87	9.06
Cash & Equivalents	47	74	96	42	-	-	-	-	8.85	2.69	8.21
Short-Term Investments	0.00	8.68	5.59	8.50	28	25	21	0.00	-	-	-
Accounts Receivable	116	36	6.25	4.47	2.66	2.01	1.91	1.53	2.92	0.84	0.08
Inventories, net	11	11	6.54	4.22	3.96	3.30	1.83	2.25	1.84	1.41	0.37
Prepaid Expenses	15	9.59	3.61	1.31	1.60	0.59	0.84	0.71	0.94	0.79	0.24
Plant, Property, & Equipment, net	3.73	3.52	3.49	3.14	3.87	5.38	6.38	6.22	7.30	2.66	0.24
Total Noncurrent Assets	196	169	36	35	13	18	10	8.90	5.20	5.60	0.94
Goodwill	0.33	0.33	0.33	0.33	0.33	0.33	2.23	2.23	2.23	2.47	0.33
Intangible Assets	187	162	26	17	2.52	2.34	3.06	2.86	2.97	3.14	0.61
Other Noncurrent Operating Assets	8.55	6.79	9.46	5.94	9.77	15	4.95	3.51	0.00	-	-
Total Liabilities & Shareholders' Equity	389	312	157	98	57	59	49	24	27	14	10
Total Liabilities	320	242	130	87	31	32	25	21	21	16	2.09
Total Current Liabilities	91	49	19	9.72	11	12	12	5.77	9.91	5.37	1.56
Short-Term Debt	0.50	-	0.72	0.28	3.90	1.77	2.53	0.60	4.43	0.50	0.06
Accounts Payable	41	25	14	6.34	3.93	7.70	6.25	3.89	3.54	3.41	0.79
Accrued Expenses	40	18	0.00	-	-	-	-	0.05	0.21	0.20	0.00
Current Deferred Revenue	0.04	0.08	0.11	0.02	0.07	0.06	0.12	0.03	-	-	-
Current Employee Benefit Liabilities	9.50	5.45	4.03	3.09	2.32	2.12	2.28	1.21	1.64	1.20	0.72
Total Noncurrent Liabilities	228	192	112	78	20	19	13	16	11	10	0.53
Long-Term Debt	220	186	104	72	12	12	12	14	7.94	8.34	0.00
Other Noncurrent Operating Liabilities	8.79	6.52	0.00	6.01	7.45	7.14	0.80	0.80	0.72	0.76	0.51
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	0.00
Total Equity & Noncontrolling Interests	69	70	27	11	27	27	25	2.62	6.43	-1.39	8.15
Total Preferred & Common Equity	70	71	28	11	27	28	25	2.62	6.43	-1.39	8.15
Total Common Equity	70	71	28	11	27	28	25	2.62	6.43	-1.39	8.15
Common Stock	221	205	137	107	105	102	99	91	83	56	50
Retained Earnings	-151	-134	-109	-95	-77	-74	-74	-89	-77	-58	-42
Noncontrolling Interest	-0.36	-0.36	-0.36	-0.36	-0.36	-0.29	0.00	-	-	-	-

This table presents Harrow Health, Inc. 11.875% Senior Notes due 2027's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	364	352	307	296	286	224	217	99
Total Current Assets	170	147	139	125	110	60	52	64
Cash & Equivalents	67	73	71	69	66	23	19	45
Accounts Receivable	77	54	52	29	18	18	12	6.74
Inventories, net	11	10	9.43	11	8.92	8.56	9.09	5.28
Prepaid Expenses	15	11	7.01	9.72	9.01	3.81	3.60	2.93
Plant, Property, & Equipment, net	3.57	3.63	3.29	3.39	3.63	3.63	3.59	3.29
Total Noncurrent Assets	191	201	164	167	172	160	162	32
Goodwill	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33
Intangible Assets	182	191	157	159	165	152	154	22
Other Noncurrent Operating Assets	8.34	9.38	6.77	6.97	6.97	7.16	7.34	7.69
Total Liabilities & Shareholders' Equity	364	352	307	296	286	224	217	99
Total Liabilities	308	294	248	235	211	202	196	98
Total Current Liabilities	187	95	54	42	19	23	18	18
Short-Term Debt	108	38	0.77	0.80	0.79	0.76	0.74	0.70
Accounts Payable	39	25	22	15	13	18	14	14
Accrued Expenses	31	25	25	21	-	-	-	-
Current Deferred Revenue	0.15	0.14	0.25	0.11	0.15	0.13	0.07	0.12
Current Employee Benefit Liabilities	7.61	7.19	5.72	5.03	5.32	4.29	3.10	3.44
Other Current Liabilities	0.61	-	-	-	-	-	-	0.00
Total Noncurrent Liabilities	121	199	195	194	192	179	178	80
Long-Term Debt	113	186	185	184	182	170	169	72
Other Noncurrent Operating Liabilities	8.58	2.71	2.71	2.71	2.71	2.28	2.28	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	56	58	58	60	75	22	22	0.86
Total Preferred & Common Equity	56	58	59	61	76	22	22	1.22
Total Common Equity	56	58	59	61	76	22	22	1.22
Common Stock	226	216	212	208	201	143	138	112
Retained Earnings	-169	-158	-154	-147	-125	-120	-116	-111
Noncontrolling Interest	-0.36	-0.36	-0.36	-0.36	-0.36	-0.36	-0.36	-0.36

This table displays calculated financial ratios and metrics derived from Harrow Health, Inc. 11.875% Senior Notes due 2027's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	53.32%	46.95%	22.24%	48.30%	-4.48%	23.67%	54.52%	34.26%	105.25%	485.30%	16,500.00%
EBITDA Growth	66.70%	2,664.98%	-60.84%	222.93%	-24.65%	67.55%	71.37%	11.79%	13.08%	-38.14%	-30.99%
EBIT Growth	66,538.46%	99.66%	-147.62%	64.91%	-6.46%	24.37%	58.91%	7.31%	2.25%	-45.77%	-32.00%
NOPAT Growth	1,946.87%	-77.54%	18.90%	319.22%	108.03%	35.66%	38.73%	23.42%	-7.15%	-46.07%	-32.00%
Net Income Growth	28.39%	-73.30%	21.77%	-426.67%	-2,635.20%	-100.85%	222.03%	37.21%	-20.05%	-57.14%	-32.38%
EPS Growth	34.67%	-47.06%	0.00%	0.00%	-1,400.00%	-98.36%	201.67%	60.00%	9.64%	-49.55%	-26.14%
Operating Cash Flow Growth	-678.18%	125.22%	-66.45%	562.00%	-215.79%	38.28%	107.80%	21.51%	-0.65%	-57.90%	-58.98%
Free Cash Flow Firm Growth	54.00%	-792.54%	-187.99%	-386.98%	206.12%	66.26%	66.63%	12.36%	-16.04%	-102.19%	-52.71%
Invested Capital Growth	39.51%	361.39%	78.48%	43.68%	-9.66%	-9.09%	-0.46%	62.14%	139.45%	3,472.99%	73.59%
Revenue Q/Q Growth	18.02%	14.04%	0.16%	-22.15%	136.50%	-15.69%	55.62%	6.12%	12.97%	43.66%	49.21%
EBITDA Q/Q Growth	228.52%	-15.44%	108.04%	-93.72%	92.62%	-115.56%	74.50%	22.53%	11.37%	-14.06%	-8.93%
EBIT Q/Q Growth	196.22%	-100.20%	66.42%	-107.39%	77.82%	-220.72%	63.26%	15.84%	7.84%	-15.14%	-9.22%
NOPAT Q/Q Growth	198.55%	-87.78%	-1.18%	-96.49%	101.40%	-217.57%	53.26%	10.04%	6.95%	-15.10%	-9.22%
Net Income Q/Q Growth	47.67%	-71.81%	37.56%	-463.70%	79.11%	-100.48%	185.95%	21.75%	-5.40%	-17.60%	-9.32%
EPS Q/Q Growth	47.87%	0.00%	0.00%	0.00%	-85.71%	-98.53%	303.33%	34.07%	6.25%	-17.73%	-9.90%
Operating Cash Flow Q/Q Growth	-619.59%	144.82%	-56.58%	-15.38%	-198.39%	228.73%	60.14%	18.09%	8.66%	-12.61%	-13.04%
Free Cash Flow Firm Q/Q Growth	-88.36%	14.52%	-70.95%	-119.86%	110.21%	-124.37%	67.69%	-19.84%	9.03%	-12.43%	-9.18%
Invested Capital Q/Q Growth	11.01%	-9.26%	24.93%	6.11%	3.22%	4.88%	-9.50%	19.60%	-4.80%	8.32%	24.29%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	75.33%	69.55%	71.35%	74.87%	70.41%	67.26%	60.07%	49.56%	50.70%	46.42%	34.16%
EBITDA Margin	13.72%	12.62%	0.67%	2.09%	-2.53%	-1.93%	-7.37%	-39.81%	-60.59%	-143.06%	-606.14%
Operating Margin	4.42%	0.33%	2.17%	2.23%	0.79%	-9.37%	-12.61%	-45.43%	-79.64%	-152.55%	-611.27%
EBIT Margin	4.33%	-0.01%	-4.35%	-2.15%	-9.07%	-8.14%	-13.31%	-50.05%	-72.50%	-152.23%	-611.27%
Profit (Net Income) Margin	-8.76%	-18.75%	-15.90%	-24.85%	-7.00%	-0.24%	35.35%	-44.76%	-95.71%	-163.64%	-609.52%
Tax Burden Percent	100.93%	102.96%	100.54%	100.74%	100.12%	106.84%	100.00%	92.76%	99.42%	100.00%	100.00%
Interest Burden Percent	-200.53%	182,384.62%	363.64%	1,148.71%	77.02%	2.81%	-265.57%	96.41%	132.78%	107.49%	99.71%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	2.97%	0.29%	4.58%	6.32%	1.74%	-19.69%	-29.15%	-58.71%	-141.75%	-462.77%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-14.18%	-43.27%	-145.87%	1,900.12%	33.34%	-55.45%	441.38%	-93.49%	-291.57%	21.54%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-28.00%	-50.28%	-78.38%	-101.70%	-14.35%	19.21%	136.03%	-206.24%	-614.62%	-7.26%	0.00%
Return on Equity (ROE)	-25.03%	-50.00%	-73.80%	-95.38%	-12.61%	-0.48%	106.88%	-264.95%	-756.37%	-470.04%	-87.00%
Cash Return on Invested Capital (CROIC)	-30.02%	-128.46%	-51.79%	-29.53%	11.90%	-10.16%	-28.69%	-106.12%	-223.91%	-327.49%	0.00%
Operating Return on Assets (OROA)	2.46%	-0.01%	-3.01%	-2.00%	-7.61%	-7.67%	-15.01%	-52.38%	-69.88%	-121.37%	-78.04%
Return on Assets (ROA)	-4.99%	-10.40%	-11.02%	-23.12%	-5.87%	-0.23%	39.87%	-46.85%	-92.26%	-130.46%	-77.82%
Return on Common Equity (ROCE)	-25.15%	-50.36%	-75.18%	-97.17%	-12.76%	-0.48%	106.88%	-264.95%	-756.37%	-470.04%	-87.00%
Return on Equity Simple (ROE_SIMPLE)	-25.10%	-34.50%	-51.05%	-159.55%	-12.58%	-0.45%	59.09%	-458.32%	-296.75%	1,147.94%	-124.15%
Net Operating Profit after Tax (NOPAT)	6.18	0.30	1.34	1.13	0.27	-3.36	-5.22	-8.51	-11	-10	-7.10
NOPAT Margin	3.09%	0.23%	1.52%	1.56%	0.55%	-6.56%	-12.61%	-31.80%	-55.75%	-106.79%	-427.89%
Net Nonoperating Expense Percent (NNEP)	17.15%	43.55%	150.45%	-1,893.80%	-31.60%	35.76%	-470.52%	34.78%	149.82%	-484.31%	-25.21%
Return On Investment Capital (ROIC_SIMPLE)	2.13%	0.12%	-	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	24.67%	30.45%	28.65%	25.13%	29.59%	32.74%	39.93%	50.44%	49.30%	53.58%	65.84%
SG&A Expenses to Revenue	64.66%	63.82%	65.74%	57.01%	63.94%	64.67%	70.68%	93.45%	88.10%	128.69%	487.17%
R&D to Revenue	6.13%	5.11%	3.44%	15.29%	4.94%	4.07%	1.99%	1.54%	3.71%	3.42%	14.28%
Operating Expenses to Revenue	70.91%	69.22%	69.18%	72.64%	69.62%	76.64%	72.68%	94.99%	130.34%	198.97%	645.42%
Earnings before Interest and Taxes (EBIT)	8.64	-0.01	-3.85	-1.56	-4.43	-4.17	-5.51	-13	-14	-15	-10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	27	16	0.59	1.52	-1.23	-0.99	-3.05	-11	-12	-14	-10
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	17.15	5.56	14.66	20.60	6.50	7.07	5.35	13.35	5.15	0.00	8.52
Price to Tangible Book Value (P/TBV)	0.00	0.00	283.75	0.00	7.26	7.82	6.80	0.00	26.87	0.00	9.63
Price to Revenue (P/Rev)	5.99	3.02	4.57	3.21	3.61	3.83	3.20	1.30	1.66	6.91	41.82
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	1,165.75	9.06	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.09%	11.04%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	5.65	2.86	11.02	11.50	11.19	11.36	7.03	2.80	3.41	15.82	0.00
Enterprise Value to Revenue (EV/Rev)	6.85	3.81	4.68	3.34	3.36	3.60	3.03	1.88	1.89	7.52	36.82
Enterprise Value to EBITDA (EV/EBITDA)	49.94	30.20	698.05	159.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	158.31	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	221.41	1,644.29	308.67	214.40	608.91	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	129.19	243.19	47.66	0.00	194.07	182.77	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	89.26	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.18	2.64	4.12	6.58	0.61	0.51	0.59	5.86	2.13	-6.38	0.01
Long-Term Debt to Equity	3.17	2.64	4.09	6.56	0.46	0.45	0.48	5.63	1.44	-6.02	0.00
Financial Leverage	1.97	1.16	0.54	-0.05	-0.43	-0.35	0.31	2.21	2.11	-0.34	-1.03
Leverage Ratio	5.02	4.81	6.70	4.13	2.15	2.08	2.68	5.66	8.20	3.60	1.12
Compound Leverage Factor	-10.06	8,769.72	24.36	47.40	1.65	0.06	-7.12	5.45	10.89	3.87	1.11
Debt to Total Capital	76.05%	72.53%	80.47%	86.81%	37.78%	33.83%	36.99%	85.42%	68.03%	118.58%	0.90%
Short-Term Debt to Total Capital	0.17%	0.00%	0.52%	0.34%	9.04%	4.28%	6.44%	3.33%	22.03%	6.76%	0.67%
Long-Term Debt to Total Capital	75.88%	72.53%	79.95%	86.47%	28.74%	29.55%	30.55%	82.09%	46.00%	111.82%	0.23%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-0.12%	-0.14%	-0.25%	-0.43%	-0.82%	-0.71%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	24.07%	27.61%	19.79%	13.62%	63.04%	66.88%	63.01%	14.58%	31.97%	-18.58%	99.10%
Debt to EBITDA	8.04	11.32	188.94	47.43	-13.20	-14.16	-4.76	-1.44	-1.13	-0.64	-0.01
Net Debt to EBITDA	6.31	6.28	17.46	6.68	9.86	11.30	2.26	-1.44	-0.38	-0.43	0.82
Long-Term Debt to EBITDA	8.02	11.32	187.72	47.24	-10.04	-12.37	-3.93	-1.38	-0.77	-0.60	0.00
Debt to NOPAT	35.63	616.13	83.55	63.68	60.46	-4.18	-2.78	-1.80	-1.23	-0.85	-0.01
Net Debt to NOPAT	27.98	341.79	7.72	8.98	-45.13	3.33	1.32	-1.80	-0.42	-0.58	1.17
Long-Term Debt to NOPAT	35.55	616.13	83.01	63.43	45.99	-3.65	-2.30	-1.73	-0.83	-0.80	0.00
Altman Z-Score	2.59	1.14	2.13	1.54	2.80	3.07	2.09	-4.79	-3.80	-5.85	11.96
Noncontrolling Interest Sharing Ratio	-0.51%	-0.73%	-1.86%	-1.88%	-1.19%	-0.56%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.08	2.83	6.35	6.24	3.80	2.93	2.76	1.53	1.49	1.09	5.81
Quick Ratio	1.79	2.41	5.80	5.67	2.88	2.22	1.96	0.28	1.19	0.66	5.32
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-62	-136	-15	-5.28	1.84	-1.73	-5.14	-15	-18	-15	-7.48
Operating Cash Flow to CapEx	-1,391.97%	263.01%	66.42%	284.55%	-129.56%	64.89%	38.86%	-1,335.81%	-162.84%	-733.57%	-4,055.75%
Free Cash Flow to Firm to Interest Expense	-2.74	-5.06	-2.10	-0.85	0.82	-0.69	-1.88	-5.09	-3.70	-13.66	0.00
Operating Cash Flow to Interest Expense	-0.97	0.14	0.24	0.82	-0.49	0.38	0.25	-2.91	-2.37	-10.06	0.00
Operating Cash Flow Less CapEx to Interest Expense	-1.04	0.09	-0.12	0.53	-0.87	-0.21	-0.40	-3.13	-3.82	-11.43	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.57	0.55	0.69	0.93	0.84	0.94	1.13	1.05	0.96	0.80	0.13
Accounts Receivable Turnover	2.62	6.13	16.53	20.32	20.93	26.08	24.03	12.03	10.60	21.10	0.00
Inventory Turnover	4.57	4.55	4.72	4.45	3.98	6.52	8.09	6.60	6.04	5.83	0.00
Fixed Asset Turnover	55.03	37.16	26.74	20.68	10.57	8.71	6.57	3.96	4.01	6.70	12.30
Accounts Payable Turnover	1.49	2.07	2.52	3.55	2.49	2.40	3.26	3.64	2.83	2.48	1.99
Days Sales Outstanding (DSO)	139.55	59.59	22.08	17.96	17.44	13.99	15.19	30.33	34.42	17.30	0.00
Days Inventory Outstanding (DIO)	79.93	80.15	77.35	81.95	91.65	55.95	45.10	55.27	60.39	62.57	0.00
Days Payable Outstanding (DPO)	244.55	176.57	144.57	102.89	146.80	152.02	111.96	100.31	128.93	147.02	183.49
Cash Conversion Cycle (CCC)	-25.06	-36.84	-45.14	-2.98	-37.71	-82.08	-51.67	-14.71	-34.12	-67.15	-183.49
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	242	174	38	21	15	16	18	18	11	4.62	-0.14
Invested Capital Turnover	0.96	1.23	3.02	4.06	3.16	3.00	2.31	1.85	2.54	4.33	-5.06
Increase / (Decrease) in Invested Capital	69	136	17	6.41	-1.57	-1.62	-0.08	6.88	6.44	4.76	0.38
Enterprise Value (EV)	1,367	496	415	242	164	184	126	50	38	73	61
Market Capitalization	1,195	393	405	232	177	196	132	35	33	67	69
Book Value per Share	$1.96	$2.02	$1.01	$0.42	$1.06	$1.10	$1.06	$0.13	$0.49	($0.14)	$0.88
Tangible Book Value per Share	($3.30)	($2.61)	$0.05	($0.23)	$0.94	$0.99	$0.84	($0.12)	$0.09	($0.72)	$0.78
Total Capital	289	256	139	83	43	41	39	18	20	7.46	8.22
Total Debt	220	186	112	72	16	14	15	15	14	8.84	0.07
Total Long-Term Debt	220	186	112	72	12	12	12	15	9.26	8.34	0.02
Net Debt	173	103	10	10	-12	-11	-6.89	15	4.63	6.01	-8.29
Capital Expenditures (CapEx)	1.60	1.46	2.57	1.79	0.85	1.46	1.77	0.66	6.89	1.52	0.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)	52	7.37	-1.51	0.55	5.63	0.33	2.05	3.63	0.23	-1.83	-0.81
Debt-free Net Working Capital (DFNWC)	99	90	100	51	34	26	23	3.63	9.28	1.00	7.55
Net Working Capital (NWC)	98	90	100	51	30	24	21	3.03	4.85	0.50	7.50
Net Nonoperating Expense (NNE)	24	25	15	19	3.69	-3.23	-20	3.47	7.97	5.52	3.02
Net Nonoperating Obligations (NNO)	173	103	10	10	-12	-11	-6.89	15	4.63	6.01	-8.29
Total Depreciation and Amortization (D&A)	19	16	4.45	3.07	3.20	3.18	2.46	2.74	2.38	0.89	0.09
Debt-free, Cash-free Net Working Capital to Revenue	25.83%	5.66%	-1.70%	0.76%	11.51%	0.65%	4.96%	13.56%	1.13%	-18.86%	-48.80%
Debt-free Net Working Capital to Revenue	49.50%	69.23%	113.27%	70.67%	69.74%	49.90%	56.73%	13.56%	46.53%	10.32%	454.88%
Net Working Capital to Revenue	49.25%	69.23%	112.45%	70.29%	61.76%	46.44%	50.62%	11.32%	24.31%	5.14%	451.57%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.49)	($0.75)	($0.51)	($0.69)	($0.13)	$0.01	$0.67	$0.60	($1.50)	($1.66)	($1.11)
Adjusted Weighted Average Basic Shares Outstanding	35.65M	32.62M	27.46M	27.03M	25.90M	25.32M	21.92M	20.78M	18.63M	13.11M	9.34M
Adjusted Diluted Earnings per Share	($0.49)	($0.75)	$0.00	($0.69)	($0.13)	$0.01	$0.61	$0.60	($1.50)	($1.66)	($1.11)
Adjusted Weighted Average Diluted Shares Outstanding	35.65M	32.62M	29.97M	27.03M	25.90M	26.47M	23.81M	20.78M	18.63M	13.11M	9.34M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($0.69)	$0.00	$0.00	$0.00	$0.60	($1.50)	($1.66)	($1.11)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	35.65M	35.36M	29.97M	26.76M	25.98M	25.53M	24.69M	20.03M	12.74M	9.58M	9.13M
Normalized Net Operating Profit after Tax (NOPAT)	6.35	0.57	1.34	1.30	0.52	-0.53	-3.65	-8.51	-11	-10	-7.10
Normalized NOPAT Margin	3.18%	0.44%	1.52%	1.80%	1.07%	-1.03%	-8.83%	-31.80%	-54.69%	-106.79%	-427.89%
Pre Tax Income Margin	-8.68%	-18.21%	-15.81%	-24.66%	-6.99%	-0.23%	35.35%	-48.26%	-96.27%	-163.64%	-609.52%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.38	0.00	-0.53	-0.25	-1.98	-1.67	-2.02	-4.43	-3.05	-13.35	0.00
NOPAT to Interest Expense	0.27	0.01	0.19	0.18	0.12	-1.34	-1.91	-2.81	-2.35	-9.36	0.00
EBIT Less CapEx to Interest Expense	0.31	-0.06	-0.89	-0.54	-2.36	-2.25	-2.67	-4.65	-4.50	-14.72	0.00
NOPAT Less CapEx to Interest Expense	0.20	-0.04	-0.17	-0.11	-0.26	-1.93	-2.56	-3.03	-3.80	-10.74	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	-0.71%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-0.71%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.13%

This table displays calculated financial ratios and metrics derived from Harrow Health, Inc. 11.875% Senior Notes due 2027's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	38.29%	83.83%	43.75%	46.22%	32.50%	78.83%	50.13%	43.51%	18.01%	0.70%	21.98%
EBITDA Growth	-83.87%	5,065.16%	0.67%	-10.93%	-158.73%	-114.33%	319.31%	3,128.50%	1,217.18%	148.93%	29.51%
EBIT Growth	-62.74%	354.03%	-14.46%	-27.51%	-657.06%	-434.79%	143.05%	327.41%	257.83%	124.22%	18.65%
NOPAT Growth	-62.12%	509.01%	-24.25%	-34.95%	-672.56%	-91.93%	1,955.32%	39.17%	-42.41%	-44.73%	97.47%
Net Income Growth	-31.07%	174.08%	3.89%	-53.06%	-104.20%	-967.11%	32.07%	32.22%	-172.48%	114.22%	22.38%
EPS Growth	-31.58%	173.08%	7.69%	-28.57%	-72.73%	0.00%	45.83%	39.13%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	524.98%	-304.45%	344.29%	-160.14%	43.66%	334.27%	-194.63%	-6.05%	-949.43%	-149.13%	80.25%
Free Cash Flow Firm Growth	-350.17%	60.81%	83.79%	93.79%	94.51%	-660.71%	-1,450.41%	-601.87%	-2,140.19%	-139.91%	-24.99%
Invested Capital Growth	19.49%	39.51%	14.04%	5.74%	2.63%	361.39%	535.20%	494.92%	0.00%	78.48%	51.61%
Revenue Q/Q Growth	-28.43%	35.68%	0.65%	41.50%	-4.86%	6.10%	2.38%	28.22%	28.40%	-10.93%	-2.14%
EBITDA Q/Q Growth	-127.04%	227.24%	-0.80%	309.43%	-630.32%	-106.63%	-12.23%	38.09%	78.27%	201.51%	-1,392.00%
EBIT Q/Q Growth	-188.87%	853.81%	-15.93%	122.83%	-38.73%	-421.18%	-28.75%	75.46%	-16.62%	141.30%	-276.36%
NOPAT Q/Q Growth	-156.33%	1,409.42%	-13.66%	122.08%	-42.11%	-379.53%	-25.85%	94.38%	147.64%	-2,602.13%	-105.56%
Net Income Q/Q Growth	-362.36%	260.59%	34.81%	52.28%	-48.28%	-108.34%	-3.83%	36.34%	-729.67%	116.32%	-3.61%
EPS Q/Q Growth	-363.16%	258.33%	33.33%	52.63%	-46.15%	-100.00%	7.14%	36.36%	0.00%	0.00%	-4.35%
Operating Cash Flow Q/Q Growth	210.62%	-702.47%	207.47%	40.67%	-153.22%	819.87%	-126.46%	155.59%	-121.28%	-805.37%	-108.44%
Free Cash Flow Firm Q/Q Growth	22.80%	-110.59%	-198.86%	7.35%	93.50%	12.87%	-14.54%	18.13%	-831.06%	-77.59%	48.15%
Invested Capital Q/Q Growth	-13.18%	11.01%	21.47%	2.07%	-1.26%	-9.26%	12.63%	-0.92%	355.68%	24.93%	5.48%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	67.54%	78.85%	75.60%	74.38%	69.49%	68.91%	70.62%	70.12%	68.31%	69.67%	70.55%
EBITDA Margin	-10.56%	27.93%	11.58%	11.75%	-7.94%	-1.03%	16.54%	19.29%	17.91%	12.90%	-11.32%
Operating Margin	-23.48%	19.30%	2.68%	3.13%	-20.03%	-13.41%	5.09%	7.03%	4.64%	-8.75%	-0.41%
EBIT Margin	-23.48%	18.91%	2.69%	3.22%	-19.96%	-13.68%	4.52%	6.50%	4.75%	7.31%	-15.76%
Profit (Net Income) Margin	-37.17%	10.14%	-8.57%	-13.23%	-39.22%	-25.16%	-12.81%	-12.64%	-25.45%	5.19%	-28.32%
Tax Burden Percent	100.00%	108.21%	100.48%	111.26%	100.00%	94.47%	153.96%	99.65%	95.84%	100.00%	100.54%
Interest Burden Percent	158.30%	49.56%	-316.98%	-369.16%	196.54%	194.63%	-184.12%	-195.22%	-559.40%	71.00%	178.68%
Effective Tax Rate	0.00%	-8.21%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-18.13%	20.06%	1.55%	1.93%	-11.20%	-11.58%	3.68%	5.10%	3.51%	-26.41%	-1.02%
ROIC Less NNEP Spread (ROIC-NNEP)	-25.48%	14.86%	-2.17%	-3.68%	-17.76%	-21.68%	-4.06%	-1.78%	-6.49%	1.22%	-39.95%
Return on Net Nonoperating Assets (RNNOA)	-59.10%	29.34%	-4.51%	-12.33%	-57.71%	-25.20%	-7.73%	-11.09%	-45.18%	0.65%	-76.81%
Return on Equity (ROE)	-77.22%	49.40%	-2.96%	-10.40%	-68.91%	-36.78%	-4.05%	-5.99%	-41.68%	-25.76%	-77.83%
Cash Return on Invested Capital (CROIC)	-16.12%	-30.02%	-16.18%	-9.00%	-5.71%	-128.46%	-143.36%	-141.25%	-199.16%	-51.79%	-35.58%
Operating Return on Assets (OROA)	-15.15%	10.77%	1.43%	1.87%	-10.79%	-7.59%	2.68%	4.14%	2.02%	5.07%	-13.82%
Return on Assets (ROA)	-23.99%	5.77%	-4.55%	-7.68%	-21.20%	-13.95%	-7.60%	-8.06%	-10.83%	3.60%	-24.83%
Return on Common Equity (ROCE)	-77.70%	49.65%	-2.98%	-10.49%	-69.50%	-37.04%	-4.09%	-6.15%	-42.36%	-26.23%	-81.07%
Return on Equity Simple (ROE_SIMPLE)	-38.43%	0.00%	-57.62%	-57.37%	-51.74%	0.00%	-18.75%	-72.66%	-83.59%	0.00%	-1,853.66%
Net Operating Profit after Tax (NOPAT)	-7.86	14	0.92	1.07	-4.85	-3.41	1.22	1.65	0.85	-1.78	-0.07
NOPAT Margin	-16.44%	20.88%	1.88%	2.19%	-14.02%	-9.39%	3.56%	4.92%	3.24%	-8.75%	-0.29%
Net Nonoperating Expense Percent (NNEP)	7.35%	5.21%	3.72%	5.61%	6.56%	10.11%	7.74%	6.88%	10.00%	-27.62%	38.93%
Return On Investment Capital (ROIC_SIMPLE)	-2.84%	4.82%	-	-	-	-1.33%	-	-	-	-	-
Cost of Revenue to Revenue	32.46%	21.15%	24.40%	25.62%	30.51%	31.09%	29.38%	29.88%	31.69%	30.33%	29.45%
SG&A Expenses to Revenue	84.70%	52.06%	68.31%	65.01%	83.31%	72.10%	61.38%	59.63%	60.87%	74.96%	67.57%
R&D to Revenue	6.33%	7.12%	4.61%	6.24%	6.21%	9.18%	4.15%	3.47%	2.81%	3.46%	3.40%
Operating Expenses to Revenue	91.03%	59.55%	72.92%	71.25%	89.52%	82.32%	65.53%	63.10%	63.68%	78.42%	70.96%
Earnings before Interest and Taxes (EBIT)	-11	13	1.33	1.58	-6.90	-4.98	1.55	2.17	1.24	1.49	-3.60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-5.05	19	5.71	5.75	-2.75	-0.38	5.67	6.46	4.68	2.62	-2.58
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	16.80	17.15	27.52	0.01	7.73	5.56	6.66	25.60	28.98	14.66	268.48
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	283.75	0.00
Price to Revenue (P/Rev)	4.46	5.99	9.43	0.00	3.37	3.02	4.42	5.58	6.85	4.57	3.69
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	5.24	5.65	8.05	0.68	3.32	2.86	3.24	4.25	4.57	11.02	11.81
Enterprise Value to Revenue (EV/Rev)	5.18	6.85	10.38	0.79	4.21	3.81	5.43	7.02	8.46	4.68	4.02
Enterprise Value to EBITDA (EV/EBITDA)	43.95	49.94	210.63	14.68	64.78	30.20	31.93	64.53	159.43	698.05	0.00
Enterprise Value to EBIT (EV/EBIT)	255.89	158.31	0.00	0.00	0.00	0.00	96.17	554.12	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	348.49	221.41	0.00	0.00	0.00	1,644.29	251.09	609.39	1,088.96	308.67	261.60
Enterprise Value to Operating Cash Flow (EV/OCF)	526.33	0.00	410.82	1,067.97	78.53	129.19	0.00	0.00	0.00	243.19	90.56
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.94	3.18	4.04	3.31	3.18	2.64	2.52	8.05	8.21	4.12	93.34
Long-Term Debt to Equity	2.01	3.17	3.39	3.29	3.17	2.64	2.51	8.01	8.17	4.09	92.53
Financial Leverage	2.32	1.97	2.08	3.35	3.25	1.16	1.90	6.23	6.96	0.54	1.92
Leverage Ratio	5.67	5.02	4.79	6.61	6.28	4.81	5.05	11.73	10.10	6.70	11.80
Compound Leverage Factor	8.98	2.49	-15.19	-24.42	12.34	9.36	-9.30	-22.91	-56.52	4.76	21.09
Debt to Total Capital	79.74%	76.05%	80.18%	76.78%	76.10%	72.53%	71.56%	88.94%	89.14%	80.47%	98.94%
Short-Term Debt to Total Capital	39.11%	0.17%	12.90%	0.31%	0.32%	0.00%	0.30%	0.38%	0.38%	0.52%	0.86%
Long-Term Debt to Total Capital	40.63%	75.88%	67.27%	76.47%	75.78%	72.53%	71.26%	88.56%	88.77%	79.95%	98.08%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-0.13%	-0.12%	-0.12%	-0.14%	-0.14%	-0.14%	-0.13%	-0.18%	-0.18%	-0.25%	-0.44%
Common Equity to Total Capital	20.39%	24.07%	19.94%	23.37%	24.05%	27.61%	28.58%	11.23%	11.04%	19.79%	1.50%
Debt to EBITDA	8.81	8.04	27.97	23.18	21.29	11.32	9.77	15.88	35.96	188.94	-10.89
Net Debt to EBITDA	6.14	6.31	19.25	14.63	12.85	6.28	5.96	13.22	30.49	17.46	-3.96
Long-Term Debt to EBITDA	4.49	8.02	23.47	23.09	21.20	11.32	9.73	15.81	35.81	187.72	-10.79
Debt to NOPAT	69.82	35.63	-37.19	-32.22	-35.53	616.13	76.82	149.97	245.60	83.55	59.19
Net Debt to NOPAT	48.72	27.98	-25.61	-20.33	-21.44	341.79	46.90	124.89	208.24	7.72	21.51
Long-Term Debt to NOPAT	35.57	35.55	-31.21	-32.09	-35.38	616.13	76.50	149.32	244.56	83.01	58.67
Altman Z-Score	1.62	2.62	3.30	0.15	1.23	1.09	1.63	1.64	1.83	2.25	1.76
Noncontrolling Interest Sharing Ratio	-0.61%	-0.51%	-0.53%	-0.89%	-0.87%	-0.73%	-0.93%	-2.59%	-1.65%	-1.86%	-4.15%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.91	2.08	1.55	2.60	3.00	2.83	5.80	2.62	2.92	6.35	3.49
Quick Ratio	0.77	1.79	1.33	2.30	2.51	2.41	4.85	2.08	2.20	5.80	3.04
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-42	-55	-26	-8.68	-9.36	-139	-160	-140	-171	-18	-10
Operating Cash Flow to CapEx	11,569.41%	-3,203.42%	488.58%	-798.26%	-5,030.43%	4,482.47%	-232.31%	1,826.40%	-1,656.05%	-422.78%	-38.86%
Free Cash Flow to Firm to Interest Expense	-6.44	-8.56	-4.69	-1.59	-1.73	-27.19	-27.81	-24.48	-16.70	-9.86	-5.73
Operating Cash Flow to Interest Expense	3.00	-2.79	0.53	-0.50	-0.85	1.70	-0.21	0.80	-0.80	-2.00	-0.23
Operating Cash Flow Less CapEx to Interest Expense	2.98	-2.88	0.42	-0.56	-0.87	1.66	-0.30	0.76	-0.85	-2.47	-0.81
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.65	0.57	0.53	0.58	0.54	0.55	0.59	0.64	0.43	0.69	0.88
Accounts Receivable Turnover	4.02	2.62	4.69	4.39	6.75	6.13	9.06	8.21	7.64	16.53	16.23
Inventory Turnover	5.04	4.57	4.87	4.95	4.21	4.55	4.86	4.55	3.05	4.72	5.28
Fixed Asset Turnover	61.19	55.03	46.63	44.54	39.76	37.16	33.00	31.98	25.82	26.74	21.79
Accounts Payable Turnover	2.00	1.49	2.44	2.22	2.90	2.07	2.57	2.31	2.01	2.52	2.27
Days Sales Outstanding (DSO)	90.90	139.55	77.91	83.17	54.05	59.59	40.30	44.44	47.75	22.08	22.49
Days Inventory Outstanding (DIO)	72.46	79.93	75.03	73.80	86.64	80.15	75.15	80.17	119.86	77.35	69.16
Days Payable Outstanding (DPO)	182.74	244.55	149.62	164.54	125.91	176.57	142.20	158.29	181.82	144.57	161.09
Cash Conversion Cycle (CCC)	-19.38	-25.06	3.32	-7.57	14.78	-36.84	-26.75	-33.68	-14.22	-45.14	-69.43
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	210	242	218	180	176	174	191	170	171	38	30
Invested Capital Turnover	1.10	0.96	0.83	0.88	0.80	1.23	1.03	1.04	1.08	3.02	3.54
Increase / (Decrease) in Invested Capital	34	69	27	9.75	4.51	136	161	141	171	17	10
Enterprise Value (EV)	1,102	1,367	1,755	122	583	496	620	721	784	415	356
Market Capitalization	948	1,195	1,595	0.74	468	393	505	574	634	405	327
Book Value per Share	$1.58	$1.96	$1.63	$1,654.33	$1.71	$2.02	$2.16	$0.74	$0.73	$1.01	$0.05
Tangible Book Value per Share	($3.54)	($3.30)	($3.76)	($2,788.22)	($2.80)	($2.61)	($2.55)	($4.32)	($4.43)	$0.05	($0.76)
Total Capital	277	289	291	251	252	256	265	199	198	139	81
Total Debt	221	220	233	192	192	186	190	177	177	112	80
Total Long-Term Debt	113	220	196	192	191	186	189	177	176	112	80
Net Debt	154	173	160	121	116	103	116	148	150	10	29
Capital Expenditures (CapEx)	0.17	0.56	0.60	0.34	0.09	0.19	0.52	0.25	0.50	0.88	1.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)	24	52	17	16	8.53	7.37	18	8.38	7.84	-1.51	-2.72
Debt-free Net Working Capital (DFNWC)	91	99	90	87	85	90	92	38	35	100	46
Net Working Capital (NWC)	-17	98	52	86	84	90	91	37	34	100	46
Net Nonoperating Expense (NNE)	9.92	7.18	5.14	7.54	8.72	5.74	5.61	5.88	7.49	-2.83	6.40
Net Nonoperating Obligations (NNO)	154	173	160	121	116	103	116	148	150	10	29
Total Depreciation and Amortization (D&A)	6.18	6.03	4.38	4.18	4.16	4.60	4.12	4.28	3.44	1.14	1.01
Debt-free, Cash-free Net Working Capital to Revenue	11.34%	25.83%	10.03%	10.14%	6.15%	5.66%	15.91%	8.16%	8.47%	-1.70%	-3.07%
Debt-free Net Working Capital to Revenue	42.69%	49.50%	52.95%	56.18%	60.93%	69.23%	80.61%	37.04%	37.51%	113.27%	52.46%
Net Working Capital to Revenue	-8.20%	49.25%	30.78%	55.69%	60.36%	69.23%	79.93%	36.30%	36.70%	112.45%	51.67%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.50)	$0.19	($0.12)	($0.18)	($0.38)	($0.26)	($0.13)	($0.14)	($0.22)	$0.05	($0.24)
Adjusted Weighted Average Basic Shares Outstanding	35.83M	35.65M	35.70M	35.62M	35.47M	32.62M	34.26M	30.46M	30.12M	27.46M	27.35M
Adjusted Diluted Earnings per Share	($0.50)	$0.19	($0.12)	($0.18)	($0.38)	($0.26)	($0.13)	($0.14)	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	35.83M	35.65M	35.70M	35.62M	35.47M	32.62M	34.26M	30.46M	30.29M	27.46M	27.41M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	36.70M	35.65M	35.61M	35.48M	35.38K	35.36M	35.12M	35.12M	30.12M	29.97M	27.41M
Normalized Net Operating Profit after Tax (NOPAT)	-7.86	9.03	0.92	1.07	-4.85	-3.41	1.22	1.65	0.85	-1.24	-0.07
Normalized NOPAT Margin	-16.44%	13.51%	1.88%	2.19%	-14.02%	-9.39%	3.56%	4.92%	3.24%	-6.12%	-0.29%
Pre Tax Income Margin	-37.17%	9.37%	-8.53%	-11.89%	-39.22%	-26.63%	-8.32%	-12.68%	-26.55%	5.19%	-28.17%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-1.72	1.98	0.24	0.29	-1.27	-0.97	0.27	0.38	0.12	0.80	-2.00
NOPAT to Interest Expense	-1.20	2.19	0.17	0.20	-0.90	-0.67	0.21	0.29	0.08	-0.96	-0.04
EBIT Less CapEx to Interest Expense	-1.74	1.90	0.13	0.23	-1.29	-1.01	0.18	0.34	0.07	0.33	-2.59
NOPAT Less CapEx to Interest Expense	-1.23	2.10	0.06	0.13	-0.91	-0.70	0.12	0.24	0.03	-1.43	-0.62
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Harrow Health, Inc. 11.875% Senior Notes due 2027's Financials

When does Harrow Health, Inc. 11.875% Senior Notes due 2027's fiscal year end?

According to the most recent income statement we have on file, Harrow Health, Inc. 11.875% Senior Notes due 2027's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Harrow Health, Inc. 11.875% Senior Notes due 2027's net income changed over the last 10 years?

Harrow Health, Inc. 11.875% Senior Notes due 2027's net income appears to be on an upward trend, with a most recent value of -$17.48 million in 2024, rising from -$10.12 million in 2014. The previous period was -$24.41 million in 2023.

What is Harrow Health, Inc. 11.875% Senior Notes due 2027's operating income?

Harrow Health, Inc. 11.875% Senior Notes due 2027's total operating income in 2024 was $8.82 million, based on the following breakdown:

Total Gross Profit: $150.37 million
Total Operating Expenses: $141.55 million

How has Harrow Health, Inc. 11.875% Senior Notes due 2027 revenue changed over the last 10 years?

Over the last 10 years, Harrow Health, Inc. 11.875% Senior Notes due 2027's total revenue changed from $1.66 million in 2014 to $199.61 million in 2024, a change of 11,924.9%.

How much debt does Harrow Health, Inc. 11.875% Senior Notes due 2027 have?

Harrow Health, Inc. 11.875% Senior Notes due 2027's total liabilities were at $319.67 million at the end of 2024, a 32.2% increase from 2023, and a 15,180.8% increase since 2014.

How much cash does Harrow Health, Inc. 11.875% Senior Notes due 2027 have?

In the past 10 years, Harrow Health, Inc. 11.875% Senior Notes due 2027's cash and equivalents has ranged from $0.00 in 2017 to $96.27 million in 2022, and is currently $47.25 million as of their latest financial filing in 2024.

How has Harrow Health, Inc. 11.875% Senior Notes due 2027's book value per share changed over the last 10 years?

Over the last 10 years, Harrow Health, Inc. 11.875% Senior Notes due 2027's book value per share changed from 0.88 in 2014 to 1.96 in 2024, a change of 122.1%.

Related Companies

This page (NASDAQ:HROWM) was last updated on 5/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) Financials

Frequently Asked Questions About Harrow Health, Inc. 11.875% Senior Notes due 2027's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) Financials

Annual Income Statements for Harrow Health, Inc. 11.875% Senior Notes due 2027

Quarterly Income Statements for Harrow Health, Inc. 11.875% Senior Notes due 2027

Annual Cash Flow Statements for Harrow Health, Inc. 11.875% Senior Notes due 2027

Quarterly Cash Flow Statements for Harrow Health, Inc. 11.875% Senior Notes due 2027

Annual Balance Sheets for Harrow Health, Inc. 11.875% Senior Notes due 2027

Quarterly Balance Sheets for Harrow Health, Inc. 11.875% Senior Notes due 2027

Annual Metrics And Ratios for Harrow Health, Inc. 11.875% Senior Notes due 2027

Quarterly Metrics And Ratios for Harrow Health, Inc. 11.875% Senior Notes due 2027

Frequently Asked Questions About Harrow Health, Inc. 11.875% Senior Notes due 2027's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools